Also, SSRIs have very different molecular structures. Zoloft (Sertraline hydrochloride) was the second SSRI to come to market in the United States, and it was approved by the FDA in December 30, 1991. Paxil (Paroxetine hydrochloride) was the third SSRI to come to market in the United States and was approved by the FDA in December 29, 1992. Chemical structure of Paroxetine differs from other SSRIs by having a piperidine ring.
The first drug in the SSRI class was Prozac (Fluoxetine), which hit the United States market in 1987. Luvox (Fluvoxamine maleate) was the next SSRI FDA approved in December 05, 1994.
Several different classes of medications are used to treat insomnia.
This list includes both prescription and over-the-counter sedative-hypnotic medications. These medications have largely replaced traditional benzodiazepines in the treatment of insomnia.
However, now its marketing status is "Discontinued".
Celexa (Citalopram hydrobromide) was approved by the FDA in July 17, 1998.
Low levels of serotonin and norepinephrine have not been proven to cause depression but it is widely believed that elevation of these chemicals is associated with improvement in mood in depressed people.
All selective serotonin reuptake inhibitors have the same principal mechanism of action.
Lexapro (Escitalopram oxalate) is the newest and most selective of the SSRIs approved by the FDA in August 14, 2002. The brain communicates with itself through the use of special chemicals called neurotransmitters, such as serotonin and norepinephrine.However, SSRIs differ in their potency and selectivity in inhibiting serotonin reuptake and many of them have important effects on other transporters and receptors.Each SSRI has a unique profile of multiple pharmacologic actions, which explains the differences in their efficacy and tolerabilitythe most potent serotonin reuptake blocker, but has a low selectivity for the serotonin reuptake muscarinic cholinergic receptors (most potent blocker of muscarinic receptors among the SSRIs) histamine H1 receptors nitric oxide synthase cytochrome P450 2D6 the second most potent inhibitor of serotonin reuptake and the second most selective blocker of serotonin over noradrenaline uptake dopamine reuptake (more potent dopamine uptake inhibitor than other SSRIs) All the SSRIs are licensed for major depressive disorder and are considered to be the first-line treatments of depression.They are prescribed more often for elderly patients than any other psychotropics and are the antidepressant of choice for many practitioners.The SSRIs differ in their licensed indications for non-depression disorders (which differ between countries).